Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.63 |
| ▸ | CTSK | P43235 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 7/20 | 0.55 |
| ▸ | CTSL | P07711 | 6/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | KYNU | Q16719 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28551469 | 1.00 | CAPN1 (0.63) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL21050812 | 1.00 | CAPN1 (0.63) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL30082499 | 1.00 | CAPN1 (0.63) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL13735150 | 1.00 | CAPN1 (0.63) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL17959489 | 0.90 | CAPN1 (0.72) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL17959487 | 0.90 | CAPN1 (0.72) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL10969199 | 0.90 | CAPN1 (0.72) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL6831659 | 0.90 | KYNU (0.59) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL6826924 | 0.90 | KYNU (0.59) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL1760460 | 0.90 | KYNU (0.59) | CAPN1CTSKALDH1A1ALOX15CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296930-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-09-25 | — | — | US | disclosed |
| US-12202828-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20230227450-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2023-07-20 | — | — | US | disclosed |
| US-11643410-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2023-05-09 | — | — | US | disclosed |
| CN-115916790-A | Pyrido [2,3-b ] [1,4] oxazines or tetrahydropyrido [2,3-b ] [1,4] oxazepines as IAP antagonists | 百济神州有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115368356-A | Bicyclic heterocyclic compounds and their therapeutic use | 阿斯特克斯治疗有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | ASTRAZENECA, AB (SE) | 2022-08-09 | — | — | US | disclosed |
| EP-3083616-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | Astex Therapeutics Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| US-20150353537-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150266873-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150259359-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| WO-2015092420-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| US-9018214-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-28 | — | — | US | disclosed |
| US-20140179666-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2699562-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | Astex Therapeutics Limited (GB) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143726-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202828-B2 | Bicyclic heterocycle compounds and their uses in therapy | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PC | CAPN1 4366/4885CTSK 1192/4885ALDH1A1 775/4885 |
| US-20250296930-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PC | CAPN1 4366/4885CTSK 1192/4885ALDH1A1 775/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | CAPN1 4094/4885CTSK 2199/4885ALDH1A1 1493/4885 |
| US-20150259359-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PC, BAD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CAPN1 4418/4885CTSK 998/4885ALDH1A1 733/4885 |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | CAPN1 4094/4885CTSK 2199/4885ALDH1A1 1493/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | CAPN1 4094/4885CTSK 2199/4885ALDH1A1 1493/4885 |
| US-20150353537-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PC, BAD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CAPN1 4418/4885CTSK 998/4885ALDH1A1 733/4885 |
| US-11643410-B2 | Bicyclic heterocycle compounds and their uses in therapy | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PC | CAPN1 4366/4885CTSK 1192/4885ALDH1A1 775/4885 |
| US-20140179666-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | CAPN1 4094/4885CTSK 2199/4885ALDH1A1 1493/4885 |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | CCNI, MCL1, MKI67 | CAPN1 4703/4885CTSK 1892/4885ALDH1A1 520/4885 |
| US-20150266873-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PC, BAD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CAPN1 4418/4885CTSK 998/4885ALDH1A1 733/4885 |
| US-20230227450-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PC | CAPN1 4366/4885CTSK 1192/4885ALDH1A1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.